WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, ...

Revvity faces multiple headwinds including declining biotech funding, regulatory uncertainty, and reduced academic research budgets. Despite challenges, Revvity's Q1 results beat expectations and the ...

Dipti Mehta has worked as a Senior Application Scientist at Revvity since 2022. Her research in DNA and protein assay development with LabChip GX Touch technology has generated new commercial assays.

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced a collaboration with Eli Lilly and Company (Lilly) that expands access to Lilly’s high-quality predictive models by making ...

Life sciences company Revvity (NYSE:RVTY) in Q4 CY2024, with sales up 4.8% year on year to $729.4 million. On the other hand, the company’s full-year revenue guidance of $2.83 billion at the midpoint ...

Revvity (NYSE:RVTY) is preparing to release its quarterly earnings on Monday, 2026-02-02. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect Revvity ...

Revvity emerged from the life sciences and diagnostics business of PerkinElmer (MA, USA) in May 2023 when the company divested its food, applied and enterprise services businesses. These businesses ...

Revvity Inc. (NYSE:RVTY) stock is trading higher on Monday after the company reported better-than-expected first-quarter 2025 earnings. The Waltham, Massachusetts-based company reported first-quarter ...

Life sciences company Revvity (NYSE:RVTY) reported in Q4 CY2025, with sales up 5.8% year on year to $772.1 million. The company’s full-year revenue guidance of $2.98 billion at the midpoint came in ...